• Kairos Pharma reported interim Phase 2 data showing its ENV-105 combination extended time before disease progression versus standard therapy alone.
• Results have already been presented as interim findings, supporting a shift to treat patients earlier in metastatic castration-resistant prostate cancer.
• Trial protocol was amended to broaden eligibility, testing enzalutamide with or without ENV-105 in patients with rising PSA after upfront therapy.
• Company targets completing the Phase 2 study in or before the fourth quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006533651) on October 06, 2026, and is solely responsible for the information contained therein.